Recent news on Probucol

AtheroGenics Splices the Data  -  Mar 28, 2007
Motley FoolProbucol, a predecessor antioxidant that AGI-1067 was supposed to improve upon, has produced similar mixed data results across different studies,

ACC: Investigational Antioxidant Has Mixed Results in Acute ...  -  Mar 29, 2007
MedPage Today,But the investigational drug, a monosuccinic ester of probucol, outperformed placebo in some secondary endpoints, reported an undaunted Marc A. Pfeffer, MD,

Antioxidant Therapy Fails to Reduce Events in Composite Endpoint ...  -  Mar 29, 2007
DG NewsSuccinobucol, the monosuccinic ester of probucol, is a lipophilic antioxidant that showed favourable results in preclinical and early clinical trials.

Heart Attack at AtheroGenics  -  Mar 20, 2007
Motley FoolThis is important because the drug's safety was one of its main benefits versus similar compound, probucol. So does this failed phase 3 study mean the

The Short Case On Atherogenics  -  Feb 1, 2007
Seeking Alpha,AGI-1067 is supposedly a derivative of Probucol, which had been pulled off the market for safety reasons. Given that Probucol had shown efficacy in the past

AtheroGenics: The Clock Is Ticking  -  Jan 30, 2007
Seeking Alpha,On the positive side, however, we should remember that AGI-1067 is a derivative of probucol which had induced regression of carotid atherosclerosis in the

Biotech's Big Long Shot  -  Jan 10, 2007
Forbes,Medford and his chemists came up with the approach of modifying a cholesterol-lowering drug, probucol. Marion Merrill Dow, the drug's maker, stopped selling

Book excerpt: The Ultimate New York Diet: The Fastest Way to a ...  -  Dec 6, 2006
SheKnows.com,As an added bonus, one animal study found that silymarin worked as effectively as the cholesterol-lowering drug probucol, with the additional benefit of

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional